A fluorescence polarization assay for inhibitors of Hsp90

被引:78
作者
Howes, R [1 ]
Barril, X
Dymock, BW
Grant, K
Northfield, CJ
Robertson, AGS
Surgenor, A
Wayne, J
Wright, L
James, K
Matthews, T
Cheung, KM
McDonald, E
Workman, P
Drysdale, MJ
机构
[1] Vernalis Cambridge, Granta Pk, Cambridge CB1 6GB, England
[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
关键词
Hsp90; fluorescence polarization; ATPase; SBDD; SAR; resorcinol; geldanamycin; 17AAG; radicicol; PU3;
D O I
10.1016/j.ab.2005.12.023
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Hsp90 encodes a ubiquitous molecular chaperone protein conserved among species which acts on multiple substrates, many of which are important cell-signaling proteins. Inhibition of Hsp90 function has been promoted as a mechanism to degrade client proteins involved in tumorigenesis and disease progression. Several assays to monitor inhibition of Hsp90 function currently exist but are limited in their use for a drug discovery campaign. Using data from the crystal structure of an initial hit compound, we have developed a fluorescence polarization assay to monitor binding of compounds to the ATP-binding site of Hsp90. This assay is very robust (Z' > 0.9) and can detect affinity of compounds with IC(50)s to 40 nM. We have used this assay in conjunction with cocrystal structures of small molecules to drive a structure-based design program aimed at the discovery and optimization of a novel class of potent Hsp90 inhibitors. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:202 / 213
页数:12
相关论文
共 56 条
[1]   Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities [J].
Agatsuma, T ;
Ogawa, H ;
Akasaka, K ;
Asai, A ;
Yamashita, Y ;
Mizukami, T ;
Akinaga, S ;
Saitoh, Y .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (11) :3445-3454
[2]  
AHERNE GW, 2003, METHODS MOL MED NOVE, P149
[3]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase [J].
Brunton, VG ;
Steele, G ;
Lewis, AD ;
Workman, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (05) :417-422
[6]   Hsp90 & Co. - a holding for folding [J].
Buchner, J .
TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (04) :136-141
[7]   Filter binding assay for the geldanamycin-heat shock protein 90 interaction [J].
Carreras, CW ;
Schirmer, A ;
Zhong, ZY ;
Santi, DV .
ANALYTICAL BIOCHEMISTRY, 2003, 317 (01) :40-46
[8]  
Chiosis G, 2003, MOL CANCER THER, V2, P123
[9]   A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells [J].
Chiosis, G ;
Timaul, MN ;
Lucas, B ;
Munster, PN ;
Zheng, FF ;
Sepp-Lorenzino, L ;
Rosen, N .
CHEMISTRY & BIOLOGY, 2001, 8 (03) :289-299
[10]   Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase [J].
Chiosis, G ;
Lucas, B ;
Shtil, A ;
Huezo, H ;
Rosen, N .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (11) :3555-3564